Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer

被引：0
|
作者：
Kumar Rajagopalan
David Peereboom
G. Thomas Budd
Thomas Olencki
Siva Murthy
Paul Elson
Denise McLain
Ronald Bukowski
机构：
[1] The Cleveland Clinic Foundation,Department of Hematology and Medical Oncology
[2] The Cleveland Clinic Cancer Center,Experimental Therapeutics Program
[3] The Cleveland Clinic Cancer Center,Department of Biostatistics
来源：
Investigational New Drugs | 1998年 / 16卷
关键词：
FUDR; hormone-refractory metastatic prostate cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day × 14 days every 4 weeks. A total of 79 complete cycles was administered.
引用
收藏
页码：255 / 258
页数：3
相关论文
共 50 条
  • [1] Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer
    Rajagopalan, K
    Peereboom, D
    Budd, GT
    Olencki, T
    Murthy, S
    Elson, P
    McLain, D
    Bukowski, R
    INVESTIGATIONAL NEW DRUGS, 1998, 16 (03) : 255 - 258
  • [2] A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer
    Dreicer, R
    Kemp, JD
    Stegink, LD
    Cardillo, T
    Davis, CS
    Forest, PK
    See, WA
    CANCER INVESTIGATION, 1997, 15 (04) : 311 - 317
  • [3] A phase II trial of lapatinib in hormone refractory prostate cancer
    Whang, Y. E.
    Moore, C. N.
    Armstrong, A. J.
    Rathmell, W. K.
    Godley, P. A.
    Crane, J. M.
    Grigson, G. I.
    Morris, K.
    Watkins, C. P.
    George, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Phase I/II clinical trial of gene therapy for hormone refractory metastatic prostate cancer
    Gotoh, A
    Terao, S
    Shirakawa, T
    JOURNAL OF GENE MEDICINE, 2006, 8 (03): : 371 - 372
  • [5] A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer
    Small, Eric J.
    Fontana, Joseph
    Tannir, Nizar
    DiPaola, Robert S.
    Wilding, George
    Rubin, Mark
    Iacona, Renee Bailey
    Kabbinavar, Fairooz F.
    BJU INTERNATIONAL, 2007, 100 (04) : 765 - 769
  • [6] Phase II trial of paclitaxel in front-line therapy of hormone refractory metastatic prostate cancer
    Kolevska, T.
    Goldstein, D.
    Davis, C.
    Fehrenbacher, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] A phase II trial of irinotecan in hormone-refractory prostate cancer
    Reese, DM
    Tchekmedyian, S
    Chapman, Y
    Prager, D
    Rosen, PJ
    INVESTIGATIONAL NEW DRUGS, 1999, 16 (04) : 353 - 359
  • [8] A phase II trial of irinotecan in hormone-refractory prostate cancer
    David M. Reese
    Simon Tchekmedyian
    Yvonne Chapman
    Diane Prager
    Peter J. Rosen
    Investigational New Drugs, 1998, 16 : 353 - 359
  • [9] Phase II study of topotecan in metastatic hormone-refractory prostate cancer
    Hudes, GR
    Kosierowski, R
    Greenberg, R
    Ramsey, HE
    Fox, SC
    Ozols, RF
    McAleer, CA
    Giantonio, BJ
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (03) : 235 - 240
  • [10] Phase II trial of weekly docetaxel and oral capecitabine in metastatic hormone-refractory prostate cancer.
    Marur, S.
    Heilbrun, L.
    Kucuk, O.
    Cher, M. L.
    Forman, J.
    Heath, E.
    Vaishampayan, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 250S - 250S
12345